Deals
Bankers Quit Goldman, Citigroup for Biotech Riches in Hong Kong
- Goldman’s Yeh is the latest to leave a bank for a biotech firm
- Lazard, BofA, Deutsche Bank have seen similar departures
This article is for subscribers only.
Investment bankers in Hong Kong are catching biotech fever.
At least seven senior bankers and analysts from top-tier securities firms have quit to join biotechnology companies in the city since December, responding to the industry’s growing demand for financial expertise after rule changes at Hong Kong’s stock exchange smoothed the path for biotech initial public offerings.